Hepatitis B (Infectious Disease) - Drugs in Development, 2021

September 2021 | 654 pages | ID: H2898ACC5B68EN
Global Markets Direct

Abstracts

Hepatitis B (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2021, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 46, 36, 4, 102, 43 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 8 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hepatitis B - Overview
Hepatitis B - Therapeutics Development
Hepatitis B - Therapeutics Assessment
Hepatitis B - Companies Involved in Therapeutics Development
Hepatitis B - Drug Profiles
Hepatitis B - Dormant Projects
Hepatitis B - Discontinued Products
Hepatitis B - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatitis B, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Hepatitis B - Pipeline by Abhelix LLC, 2021
Hepatitis B - Pipeline by Ai-biopharma SAS, 2021
Hepatitis B - Pipeline by AiCuris AG, 2021
Hepatitis B - Pipeline by Akshaya Bio Inc, 2021
Hepatitis B - Pipeline by Aligos Therapeutics Inc, 2021
Hepatitis B - Pipeline by AlloVir Inc, 2021
Hepatitis B - Pipeline by AlphaMab Co Ltd, 2021
Hepatitis B - Pipeline by Alphamab Oncology, 2021
Hepatitis B - Pipeline by Altimmune Inc, 2021
Hepatitis B - Pipeline by Antios Therapeutics Inc, 2021
Hepatitis B - Pipeline by Apros Therapeutics Inc, 2021
Hepatitis B - Pipeline by Arbutus Biopharma Corp, 2021
Hepatitis B - Pipeline by Arcturus Therapeutics Holdings Inc, 2021
Hepatitis B - Pipeline by Ascentage Pharma Group International, 2021
Hepatitis B - Pipeline by Ascletis Pharma Inc, 2021
Hepatitis B - Pipeline by Assembly Biosciences Inc, 2021
Hepatitis B - Pipeline by Atea Pharmaceuticals Inc, 2021
Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC, 2021
Hepatitis B - Pipeline by Auro Vaccines LLC, 2021
Hepatitis B - Pipeline by Avalia Immunotherapies Ltd, 2021
Hepatitis B - Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2021
Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, 2021
Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
Hepatitis B - Pipeline by Benitec Biopharma Inc, 2021
Hepatitis B - Pipeline by Biological E Ltd, 2021
Hepatitis B - Pipeline by Biomics Biopharma Ltd, 2021
Hepatitis B - Pipeline by BioNet-Asia Co Ltd, 2021
Hepatitis B - Pipeline by Biotron Ltd, 2021
Hepatitis B - Pipeline by Bolder Biotechnology Inc, 2021
Hepatitis B - Pipeline by Bonac Corp, 2021
Hepatitis B - Pipeline by Brandenburg Antiinfektiva GmbH, 2021
Hepatitis B - Pipeline by Brickell Biotech Inc, 2021
Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, 2021
Hepatitis B - Pipeline by Bukwang Pharmaceutical Co Ltd, 2021
Hepatitis B - Pipeline by Cadila Healthcare Ltd, 2021
Hepatitis B - Dormant Projects, 2021
Hepatitis B - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatitis B, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021